Navigation Links
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Date:11/10/2008

Company Will Host a Conference Call Today To Discuss the Data and Ongoing

Clinical Development Programs

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in a number of measures of nerve function and health at the primary analysis point, day 180 post-treatment.

Sangamo management will host a conference call at 5:00 p.m. ET today to review these data and the ongoing clinical studies supporting the development of SB-509.

"Our first Phase 2 study, SB-509-601, had three goals," stated Dale Ando, M.D., Sangamo's vice president, therapeutic development and CMO. "First, we wanted to determine the safety of repeat dosing. Second, we evaluated dose schedule, specifically whether a regimen of three administrations of the maximum dose given at two month intervals would be more effective than a single administration. Finally, we hoped to gain clarity around clinical endpoints for use in the design of future studies. While this study has not added to our data around the most suitable end-points or dosing schedule for a Phase 3 trial, it has demonstrated that the drug continues to have an excellent safety profile. This is valuable information for our future development efforts."

"We also know that SB-509 is an active agent. We have positive preclinical dat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
2. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
5. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
6. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
8. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
9. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
10. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
11. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results ... 2015 first quarter financial statements and MD&A have been filed on ... March 31,(in CDN$,000 except per share data) , 2015 ... Gross profit , 1,531 , 329 Ebitda* , ... 528 , (531) Basic earnings (loss) per share ...
(Date:6/1/2015)... 01, 2015 Regis Technologies, Inc. ... of chiral stationary phases (CSPs) for analytical and ... current and presenting solutions for new clients, Regis ... This valuable addition to its core expertise in ... that can tackle projects for the scale clients ...
(Date:6/1/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that it ... commercial food testing laboratory based in southwest India ... a base for the company,s new operations in ... was incorporated in 1990, and its business has grown ... quality testing for major hotels and restaurants in its home ...
(Date:6/1/2015)... 2015 Esperance Pharmaceuticals Inc. today reported positive ... EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 ... destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) ... a wide range of cancers. Results ... EP-100 were presented at the 2015 ASCO Annual ...
Breaking Biology Technology:Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Neogen acquires India food safety company 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... Inc., a privately held,biopharmaceutical company focused on ... today announced a company,restructuring that includes the ... significant reduction in work force, primarily in ... company,s burn rate and refocuses,Sangart,s business units ...
... 7 GlaxoSmithKline plc (LSE/NYSE: GSK ) ... by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares ... GNLB ). The tender offer expired at 12:00 ... 2009.The depositary for the tender offer has advised GSK ...
... REDWOOD CITY, Calif., Jan. 7 Codexis, Inc. today ... produce an,important publicly-undisclosed generic product, using a proprietary Codexis,biocatalyst. ... world, is a,leading producer of this generic product. ... drugs in the United States. , ...
Cached Biology Technology:Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. 2Codexis, Teva in Licensing Agreement Final 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... vaccine that enlists help from the immune system to keep ... to help smokers quit and to limit the urge to ... being developed by Nabi Biopharmaceuticals to prevent and treat nicotine ... smoker inhales, nicotine is carried by the bloodstream to the ...
... Scientists at the Albert Einstein College of Medicine of ... gene expression can occur in the form of discrete ... techniques, developed by Dr. Robert Singer and colleagues at ... directly watch the behavior of a single gene in ...
... subpopulation of helper T-cells provides immunity and promotes survival ... means of predicting an AIDS vaccine's effectiveness, a discovery ... in clinical trials. , Led by researchers at Beth ... Center (VRC) at the National Institute of Allergy and ...
Cached Biology News:Einstein researchers take the pulse of a gene in living cells 2AIDS vaccine research offers new insights on survival 2AIDS vaccine research offers new insights on survival 3
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Conjugation, Quantities to Kilograms, ... Special amino acids and their ... labeling AMC, aldehyde, CMK, Purity ... Chromogenic/Flurogenic Substrates, Solid Phase/Solution/Segment ...
... The Gla-type Osteocalcin EIA Kit is ... kit for quantitative determination of human ... cell culture supernatants, and other biological ... research use only. It is not ...
Biology Products: